CCMS announces new Chief Clinical & Development Officer

English

简体中文 繁體中文 English Filipino हिन्दी Hmong Bahasa Indonesia 日本語 Basa Jawa 한국어 ພາສາລາວ Bahasa Melayu മലയാളം ဗမာစာ سنڌي தமிழ் ไทย Tiếng Việt Afrikaans Shqip العربية አማርኛ Հայերեն Azərbaycan dili Euskara Беларуская мова বাংলা Bosanski Български Català Cebuano Chichewa Corsu Italiano Hrvatski Čeština‎ Dansk Nederlands Esperanto Eesti Suomi Frysk Galego ქართული Ελληνικά ગુજરાતી Kreyol ayisyen Deutsch Français Harshen Hausa Ōlelo Hawaiʻi עִבְרִית Magyar Íslenska Igbo Gaeilge ಕನ್ನಡ Қазақ тілі ភាសាខ្មែរ كوردی‎ Кыргызча Latin Latviešu valoda Lietuvių kalba Lëtzebuergesch Македонски јазик Malagasy Maltese Te Reo Māori मराठी Монгол नेपाली Norsk bokmål پښتو فارسی Polski Português ਪੰਜਾਬੀ Română Русский Samoan Gàidhlig Српски језик Sesotho Shona සිංහල Slovenčina Slovenščina Afsoomaali Español Basa Sunda Kiswahili Svenska Тоҷикӣ తెలుగు Türkçe Українська اردو O‘zbekcha Cymraeg isiXhosa יידיש Yorùbá Zulu

Theresa Wang, has been named the Chief Clinical & Development Officer of ClearChoice Management Services (CCMS), the administrative support group and innovation hub that supports the nationwide network of ClearChoice Dental Implant Centers. Following the retirement of Mark W. Adams at the end of 2022, she has assumed this new position. This appointment marks a new chapter for the business.

Former prosthodontist and vice president of clinical innovation

As the owner and chief prosthodontist of the ClearChoice Dental Implant Center in Schaumburg, Illinois, Dr Wang, a longtime member of the ClearChoice network, joined the business in 2012. While playing a crucial role as head of the Clinical Advisory Board for the ClearChoice network, she extended her practice to three locations in the area. She changed careers in 2022, becoming the Vice President of Clinical Innovation at CCMS, where she worked to test and roll out new clinical services and technologies across the network.

Advancing patient care and technology

Dr Wang will manage the development of new technologies and materials to improve patient outcomes and experiences in her new role as Chief Clinical & Development Officer. She will also be in charge of bringing new procedures and services across the network.

“Since joining ClearChoice over ten years ago, I’ve had a front row seat to some of the most significant advancements in implant dentistry, including the transition from analog to digital. And yet, I believe we’ve still only scratched the surface of what can be achieved with technology,” said Dr Wang. “I’m honored to take on this new role at CCMS and work alongside some of the sharpest minds in this field to advance patient care within our business and the industry.”